These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 22897467)

  • 1. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series.
    Adizie T; Christidis D; Dharmapaliah C; Borg F; Dasgupta B
    Int J Clin Pract; 2012 Sep; 66(9):906-9. PubMed ID: 22897467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis.
    Askling J; Klareskog L; Hjalgrim H; Baecklund E; Björkholm M; Ekbom A
    Ann Rheum Dis; 2005 Dec; 64(12):1765-8. PubMed ID: 15843445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors for treatment success and expression of glucocorticoid receptor in giant cell arteritis and polymyalgia rheumatica.
    Braun N; Fritz P; Rieth A; Schroth W; Kimmel M; Biegger D; Zakim D; Alscher MD
    J Rheumatol; 2009 Oct; 36(10):2269-76. PubMed ID: 19684157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series.
    Diamantopoulos AP; Hetland H; Myklebust G
    Biomed Res Int; 2013; 2013():120638. PubMed ID: 24106691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.
    Albrecht K; Huscher D; Buttgereit F; Aringer M; Hoese G; Ochs W; Thiele K; Zink A
    Rheumatol Int; 2018 Apr; 38(4):569-577. PubMed ID: 29124397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine levels in polymyalgia rheumatica and giant cell arteritis: influence of corticosteroid therapy.
    Martinez-Taboada VM; Bartolome MJ; Fernandez-Gonzalez MD; Blanco R; Rodriguez-Valverde V; Lopez-Hoyos M
    Rheumatology (Oxford); 2003 Sep; 42(9):1055-61. PubMed ID: 12730520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymyalgia rheumatica.
    Lestico MR; Boh LE; Schuna AA
    Clin Pharm; 1993 Aug; 12(8):571-80. PubMed ID: 8222521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study.
    González-Gay MA; García-Porrúa C; Vázquez-Caruncho M; Dababneh A; Hajeer A; Ollier WE
    J Rheumatol; 1999 Jun; 26(6):1326-32. PubMed ID: 10381051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis.
    Bahlas S; Ramos-Remus C; Davis P
    J Rheumatol; 1998 Jan; 25(1):99-104. PubMed ID: 9458211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis.
    Matteson EL; Buttgereit F; Dejaco C; Dasgupta B
    Rheum Dis Clin North Am; 2016 Feb; 42(1):75-90, viii. PubMed ID: 26611552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid sparing therapeutic approaches to polymyalgia rheumatica-giant cell arteritis. State of the art and perspectives.
    Ferraccioli GF; Di Poi E; Damato R
    Clin Exp Rheumatol; 2000; 18(4 Suppl 20):S58-60. PubMed ID: 10948766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?
    van der Veen MJ; Dinant HJ; van Booma-Frankfort C; van Albada-Kuipers GA; Bijlsma JW
    Ann Rheum Dis; 1996 Apr; 55(4):218-23. PubMed ID: 8733437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Polymyalgia rheumatica and temporal arteritis].
    Vos PA; Bijlsma JW; Derksen RH
    Ned Tijdschr Geneeskd; 2005 Aug; 149(35):1932-7. PubMed ID: 16159030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.
    Buttgereit F; Dejaco C; Matteson EL; Dasgupta B
    JAMA; 2016 Jun; 315(22):2442-58. PubMed ID: 27299619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review.
    Martinez-Taboada VM; Blanco R; Fito C; Pacheco MJ; Delgado-Rodriguez M; Rodriguez-Valverde V
    Semin Arthritis Rheum; 2001 Feb; 30(4):257-71. PubMed ID: 11182026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PMR and GCA: steroids or bust.
    Adizie T; Dasgupta B
    Int J Clin Pract; 2012 Jun; 66(6):524-7. PubMed ID: 22607502
    [No Abstract]   [Full Text] [Related]  

  • 17. [Management of polymyalgia rheumatica and large vessel vasculitis].
    Hellmich B
    Internist (Berl); 2016 Nov; 57(11):1069-1078. PubMed ID: 27631531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymyalgia rheumatica and giant cell arteritis--An ophthalmic emergency.
    Durkin SR; Athanasiov PA; Crompton JL
    Aust Fam Physician; 2006 Nov; 35(11):889-91. PubMed ID: 17099810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis.
    Narváez J; Nolla-Solé JM; Clavaguera MT; Valverde-García J; Roig-Escofet D
    J Rheumatol; 1999 Sep; 26(9):1945-52. PubMed ID: 10493675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate treatment in large vessel vasculitis and polymyalgia rheumatica.
    Spies CM; Burmester GR; Buttgereit F
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S172-7. PubMed ID: 21044455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.